Category: Commentary Elsewhere

Non-Appealing Cartelists Beware

Commentary Elsewhere: from writers around the web. Please note the explanation of this section on the “About the Site” page. From Competition Bulletin: Non-Appealing Cartelists Beware “Tucked away at the back of last week’s Supreme Court decision on time-limits for follow-on claims is a very important development for private competition actions. The context is section 47A of the Competition Act 1998, a provision which has generated an extraordinary amount of litigation in view of the fact that it was intended to […]”

Negotiated Remedies in the Modernization Era: The Limits of Effectiveness

Commentary Elsewhere: from writers around the web. Please note the explanation of this section on the “About the Site” page. From Antitrust & Competition Policy Blog: Negotiated Remedies in the Modernization Era: The Limits of Effectiveness “Damien M. B. Gerard, University of Louvain – CeDIE discusses Negotiated Remedies in the Modernization Era: The Limits of Effectiveness. ABSTRACT: Over the past ten years, the nature, scope and design of remedies have taken a growing importance in the…”

Remarks as Prepared for Delivery by Assistant Attorney General Bill Baer at the Pen and Pad Briefing on the Justice Department and Federal Trade Commission Joint Antitrust Policy Statement on Sharing of Cybersecurity Information

Commentary Elsewhere: from writers around the web. Please note the explanation of this section on the “About the Site” page. From Antitrust & Competition Policy Blog: Remarks as Prepared for Delivery by Assistant Attorney General Bill Baer at the Pen and Pad Briefing on the Justice Department and Federal Trade Commission Joint Antitrust Policy Statement on Sharing of Cybersecurity Information “Remarks as Prepared for Delivery by Assistant Attorney General Bill Baer at the Pen and Pad Briefing on the Justice Department and Federal Trade Commission Joint Antitrust Policy Statement on Sharing of Cybersecurity Information.”

Lundbeck, and Johnson & Johnson and Novartis: The European Commission’s 2013 ‘pay-for-delay’ decisions

Commentary Elsewhere: from writers around the web. Please note the explanation of this section on the “About the Site” page. From Journal of European Competition Law & Practice – current issue: Lundbeck, and Johnson & Johnson and Novartis: The European Commission’s 2013 ‘pay-for-delay’ decisions “”